

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 31, 2018**

---

**OVID THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(state or other jurisdiction  
of incorporation)

**001-38085**  
(Commission  
File Number)

**46-5270895**  
(I.R.S. Employer  
Identification No.)

**1460 Broadway, Suite 15044**  
**New York, New York**  
(Address of principal executive offices)

**10036**  
(Zip Code)

**Registrant's telephone number, including area code: (646) 661-7661**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 31, 2018, Yaron Werber, M.D. notified Ovid Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Chief Business and Financial Officer as well as all other positions he holds at the Company. Dr. Werber will remain with the Company as its Chief Business and Financial Officer through September 21, 2018. Dr. Werber has accepted a position as managing director and senior biotechnology analyst at Cowen and Company and did not resign as a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including its controls or financial-related matters. The Company has commenced a search for a new Chief Financial Officer.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OVID THERAPEUTICS INC.**

By: /s/ Ana C. Ward \_\_\_\_\_

Ana C. Ward

Senior Vice President, General Counsel

Dated: September 4, 2018